Comparison between free β subunit of human chorionic gonadotropin (hCG) and total hCG assays in adults with testicular cancer.


Journal

Clinical chemistry and laboratory medicine
ISSN: 1437-4331
Titre abrégé: Clin Chem Lab Med
Pays: Germany
ID NLM: 9806306

Informations de publication

Date de publication:
26 09 2023
Historique:
received: 18 09 2022
accepted: 11 04 2023
medline: 21 8 2023
pubmed: 20 4 2023
entrez: 20 04 2023
Statut: epublish

Résumé

We tested the hypothesis that the free-β subunit (βhCG) is diagnostically more sensitive with total hCG assays (hCGt) not detecting all tumours secreting βhCG. The effects of sex, age, and renal failure were investigated as secondary objectives. We compared βhCG with hCGt in 204 testicular cancer patients (99 seminomas, 105 non-seminonatous germ cell tumours). The effects of sex and age were determined in 125 male and 138 female controls and that of renal failure was investigated in 119 haemodialysis patients. Biochemical assessment of gonadal status was performed with LH, FSH, oestradiol and testosterone. Discordant results were common with isolated increases of hCGt observed in 32 (15.7 %) and βhCG in 14 (6.9 %) patients. Primary hypogonadism was the most common cause of isolated hCGt increases. After therapeutic interventions βhCG decreased below its upper reference more rapidly than hCGt. We observed unequivocal false negative results in two patients with non-seminomatous germ cell tumours. Both occurred in patients with clinical tumour recurrences; in one instance we observed a false negative hCGt while in the second false negative βhCG's were documented in serial samples. The similar false negative rates did not support the hypothesis that βhCG will detect more patients with testicular cancer than hCGt. In contrast to hCGt, βhCG was unaffected by primary hypogonadism which is a predictably frequent complication in testicular cancer patients. We therefore recommend βhCG as the preferred biomarker in testicular cancer.

Identifiants

pubmed: 37078204
pii: cclm-2022-1240
doi: 10.1515/cclm-2022-1240
doi:

Substances chimiques

Chorionic Gonadotropin 0
Chorionic Gonadotropin, beta Subunit, Human 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1841-1849

Informations de copyright

© 2023 Walter de Gruyter GmbH, Berlin/Boston.

Références

Ferraro, S, Trevisiol, C, Gion, M, Panteghini, M. Human chorionic gonadotropin assays for testicular tumors: closing the gap between clinical and laboratory practice. Clin Chem 2018;64:270–8. https://doi.org/10.1373/clinchem.2017.275263 .
doi: 10.1373/clinchem.2017.275263
Stenman, U, Alfthan, H, Hotakainen, K. Human chorionic gonadotropin in cancer. Clin Biochem 2004;37:549–61. https://doi.org/10.1016/j.clinbiochem.2004.05.008 .
doi: 10.1016/j.clinbiochem.2004.05.008
Whittington, J, Fantz, CR, Gronowski, AM, McCudden, C, Mullins, R, Sokoll, L, et al.. The analytical specificity of human chorionic gonadotropin assays determined using WHO international reference reagents. Clin Chim Acta 2010;411:81–5. https://doi.org/10.1016/j.cca.2009.10.009 .
doi: 10.1016/j.cca.2009.10.009
Pretorius, CJ, du Toit, S, Wilgen, U, Klingberg, S, Jones, M, Ungerer, JPJ, et al.. How comparable are total human chorionic gonadotropin (hCGt) tumour markers assays? Clin Chem Lab Med 2020;58:438–44. https://doi.org/10.1515/cclm-2019-0457 .
doi: 10.1515/cclm-2019-0457
Lempiäinen, A, Stenman, U, Blomqvist, C, Hotakainen, K. Free β-subunit of human chorionic gonadotropin in serum is a diagnostically sensitive marker of seminomatous testicular cancer. Clin Chem 2008;54:840–3. https://doi.org/10.1373/clinchem.2008.108548 .
doi: 10.1373/clinchem.2008.108548
Greene, DN, Petrie, MS, Pyle, AL, Kamer, SM, Grenache, DG. Performance characteristics of the Beckman Coulter total βHCG (5th IS) assay. Clin Chim Acta 2015;439:61–7. https://doi.org/10.1016/j.cca.2014.09.029 .
doi: 10.1016/j.cca.2014.09.029
Alfthan, H, Haglund, C, Dabek, J, Stenman, UH. Concentrations of human choriogonadotropin, its beta-subunit, and the core fragment of the beta-subunit in serum and urine of men and nonpregnant women. Clin Chem 1992;38:1981–7. https://doi.org/10.1093/clinchem/38.10.1981 .
doi: 10.1093/clinchem/38.10.1981
Potluri, K, Moldenhauer, J, Karlman, R, Hou, S. Beta HCG levels in a pregnant dialysis patient: a cautionary tale. NDT Plus 2011;4:42–3. https://doi.org/10.1093/ndtplus/sfq195 .
doi: 10.1093/ndtplus/sfq195
Azimi, V, Budelier, VM, Gronowski, AM. Decreased renal function is associated with mild elevations of hCG in women >40 years of age. (Letter). Clin Chem 2021;11:1567–9. https://doi.org/10.1093/clinchem/hvab177 .
doi: 10.1093/clinchem/hvab177
Pretorius, CJ, Parsonage, W, Cullen, LW, Wilgen, U, De Waal, E, Klingberg, S, et al.. Evaluation of the Atellica TnIH cardiac troponin I assay and assessment of biological equivalence. Clin Chem Lab Med 2022;60:283–90. https://doi.org/10.1515/cclm-2021-0991 .
doi: 10.1515/cclm-2021-0991
Wehmann, RE, Amr, S, Rosa, C, Nisula, BC. Metabolism, distribution and excretion of purified human chorionic gonadotropin and its subunits in man. Ann Endocrinol (Paris) 1984;45:291–5.
Valentin, M, Muller, F, Beaujard, MP, Dreux, S, Czerkiewicz, I, Meyer, V, et al.. First-trimester combined screening for trisomy 21 in women with renal disease. Prenat Diagn 2015;35:244–8. https://doi.org/10.1002/pd.4528 .
doi: 10.1002/pd.4528
Skiba, R, Matyjek, A, Syryło, T, Niemczyk, S, Rymarz, A. Advanced chronic kidney disease is a strong predictor of hypogonadism and is associated with decreased lean tissue mass. Int J Nephrol Renovascular Dis 2020;13:319–27. https://doi.org/10.2147/ijnrd.s275554 .
doi: 10.2147/ijnrd.s275554
Fizazi, K, Culine, S, Kramar, A, Amato, RJ, Bouzy, J, Chen, I, et al.. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 2004;22:3868–76. https://doi.org/10.1200/jco.2004.04.008 .
doi: 10.1200/jco.2004.04.008
Saller, B, Clara, R, Spöttl, G, Siddle, K, Mann, K. Testicular cancer secretes intact human choriogonadotropin (hCG) and its free beta-subunit: evidence that hCG (+hCG-beta) assays are the most reliable in diagnosis and follow-up. Clin Chem 2000;36:234–9.
Madersbacher, S, Klieber, R, Mann, K, Marth, C, Tabarelli, M, Wick, G, et al.. Free α-subunit, free β-subunit of human chorionic gonadotropin (hCG), and intact hCG in sera of healthy individuals and testicular cancer patients. Clin Chem 1992;38:370–6. https://doi.org/10.1093/clinchem/38.3.370 .
doi: 10.1093/clinchem/38.3.370
Hoshi, S, Suzuki, K, Ishidoya, S, Ohyama, C, Sato, M, Namima, T, et al.. Significance of simultaneous determination of serum human chorionic gonadotropin (hCG) and hCG-beta in testicular tumor patients. Int J Urol 2000;7:218–23. https://doi.org/10.1046/j.1442-2042.2000.00181.x .
doi: 10.1046/j.1442-2042.2000.00181.x
Lempiäinen, A, Hotakainen, K, Blomqvist, C, Alfthan, H, Stenman, U. Increased human chorionic gonadotropin due to hypogonadism after treatment of a testicular seminoma (letter). Clin Chem 2007;53:1560–1. https://doi.org/10.1373/clinchem.2007.088518 .
doi: 10.1373/clinchem.2007.088518
Ferraro, S, Panteghini, M. A step forward in identifying the right human chorionic gonadotropin assay for testicular cancer. Clin Chem Lab Med 2020;58:357–60. https://doi.org/10.1515/cclm-2019-0319 .
doi: 10.1515/cclm-2019-0319
Ferraro, S, Incarbone, G, Rossi, R, Dolci, A, Panteghini, M. Human chorionic gonadotropin in oncology: a matter of tight (bio)marking. Clin Chem Lab Med 2020;58:e57–60. https://doi.org/10.1515/cclm-2019-0629 .
doi: 10.1515/cclm-2019-0629
Trapé, J, Franquesa, J, Sala, M, Domenech, M, Montesinos, J, Catot, S, et al.. Determination of biological variation of α-fetoprotein and choriogonadotropin (β chain) in disease-free patients with testicular cancer. Clin Chem Lab Med 2010;48:1799–801. https://doi.org/10.1515/cclm.2010.343 .
doi: 10.1515/cclm.2010.343
Ferraro, S, Panzeri, A, Braga, F, Panteghini, M. Serum α-fetoprotein in pediatric oncology: not a children’s tale. Clin Chem Lab Med 2019;57:783–97. https://doi.org/10.1515/cclm-2018-0803 .
doi: 10.1515/cclm-2018-0803

Auteurs

Carel J Pretorius (CJ)

Chemical Pathology, Pathology Queensland, Herston, QLD, Australia.
Faculty of Medicine, The University of Queensland, Brisbane, Australia.

Urs Wilgen (U)

Chemical Pathology, Pathology Queensland, Herston, QLD, Australia.
Faculty of Medicine, The University of Queensland, Brisbane, Australia.

Sandra Klingberg (S)

Chemical Pathology, Pathology Queensland, Herston, QLD, Australia.

Anna Zournazi (A)

Chemical Pathology, Pathology Queensland, Herston, QLD, Australia.

Linda Sanders (L)

Chemical Pathology, Pathology Queensland, Herston, QLD, Australia.

Jacobus P J Ungerer (JPJ)

Chemical Pathology, Pathology Queensland, Herston, QLD, Australia.
Faculty of Medicine, The University of Queensland, Brisbane, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH